Guideline decision tool · Respiratory
🫁

Acute Pulmonary Embolism Risk Stratification & Treatment — free guideline decision tool

This tool stratifies acute pulmonary embolism by hemodynamics, sPESI/PESI, right-heart function, and troponin, and gives the reperfusion or anticoagulation direction per ESC 2019.

Open guideline tool →
Computed locally — no data uploaded. For licensed clinicians.
📋

Guideline-based

Implements the decision logic from published clinical guidelines.

🖥️

Runs in your browser

No installation. Enter the patient's values and get a guideline recommendation instantly.

🔒

Data stays local

Nothing is uploaded. Results are for licensed clinicians only.

Worked calculation

The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.

Hemodynamically unstable (shock/persistent hypotension)Yes
sPESI ≥ 1 or PESI III-V (suggests risk)Yes
Right-heart dysfunction (TTE/CTPA, RV/LV ≥ 1.0)Present
Elevated troponinPresent

Risk stratificationHigh-risk PE

  • DecisionHemodynamically unstable (shock or persistent hypotension) = high-risk
  • ReperfusionImmediate systemic thrombolysis (preferred, greatest benefit within 48 h of onset); thrombolysis contraindicated or failed → catheter-directed therapy or surgical embolectomy
  • Anticoagulation/supportSimultaneously start parenteral anticoagulation (unfractionated heparin); hemodynamic support (cautious fluids, norepinephrine if needed), ECMO bridging possible
Hemodynamically unstable (shock/persistent hypotension)No
sPESI ≥ 1 or PESI III-V (suggests risk)No (sPESI = 0)
Right-heart dysfunction (TTE/CTPA, RV/LV ≥ 1.0)Absent
Elevated troponinAbsent

Risk stratificationLow-risk PE

  • DecisionHemodynamically stable; sPESI = 0
  • ManagementAnticoagulation suffices (NOAC preferred); eligible patients may be considered for early discharge/home treatment (e.g. Hestia criteria)
  • AnticoagulationNOAC preferred (except severe renal impairment, antiphospholipid syndrome, pregnancy, etc., where LMWH/warfarin is used); at least 3 months, assess extension by provoking factors and recurrence risk

Common questions

What is Acute Pulmonary Embolism Risk Stratification & Treatment?

This tool stratifies acute pulmonary embolism by hemodynamics, sPESI/PESI, right-heart function, and troponin, and gives the reperfusion or anticoagulation direction per ESC 2019.

How is Acute Pulmonary Embolism Risk Stratification & Treatment calculated? What is the core formula?

Unstable → high-risk, systemic thrombolysis + anticoagulation. Stable: RV + troponin both positive → intermediate-high (monitor, rescue thrombolysis); one positive/high score → intermediate-low; sPESI = 0 and normal RV/troponin → low-risk. NOAC preferred.

When is Acute Pulmonary Embolism Risk Stratification & Treatment used?

Use to assign risk and treatment: high-risk PE needs immediate reperfusion, while stable patients are anticoagulated and monitored, with rescue reperfusion reserved for decompensation.

What are the key clinical points for Acute Pulmonary Embolism Risk Stratification & Treatment?

Intermediate-high-risk PE is anticoagulated with close monitoring, reserving rescue reperfusion for hemodynamic decompensation rather than upfront thrombolysis. (original synthesis · not guideline verbatim) Low-risk patients meeting criteria (e.g. Hestia) may be considered for early discharge or home treatment. NOACs are preferred except in severe renal impairment, antiphospholipid syndrome, or pregnancy, with at least 3 months of therapy.

What are the limits and cautions when using Acute Pulmonary Embolism Risk Stratification & Treatment?

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

How is Acute Pulmonary Embolism Risk Stratification & Treatment calculated in practice? Can you show a worked example?

Inputs: Hemodynamically unstable (shock/persistent hypotension) Yes, sPESI ≥ 1 or PESI III-V (suggests risk) Yes, Right-heart dysfunction (TTE/CTPA, RV/LV ≥ 1.0) Present, Elevated troponin Present → Result: Risk stratification High-risk PE(Decision: Hemodynamically unstable (shock or persistent hypotension) = high-risk, Reperfusion: Immediate systemic thrombolysis (preferred, greatest benefit within 48 h of onset); thrombolysis contraindicated or failed → catheter-directed therapy or surgical embolectomy, Anticoagulation/support: Simultaneously start parenteral anticoagulation (unfractionated heparin); hemodynamic support (cautious fluids, norepinephrine if needed), ECMO bridging possible) Inputs: Hemodynamically unstable (shock/persistent hypotension) No, sPESI ≥ 1 or PESI III-V (suggests risk) No (sPESI = 0), Right-heart dysfunction (TTE/CTPA, RV/LV ≥ 1.0) Absent, Elevated troponin Absent → Result: Risk stratification Low-risk PE(Decision: Hemodynamically stable; sPESI = 0, Management: Anticoagulation suffices (NOAC preferred); eligible patients may be considered for early discharge/home treatment (e.g. Hestia criteria), Anticoagulation: NOAC preferred (except severe renal impairment, antiphospholipid syndrome, pregnancy, etc., where LMWH/warfarin is used); at least 3 months, assess extension by provoking factors and recurrence risk)

🫁

Run Acute Pulmonary Embolism Risk Stratification & Treatment now

This tool stratifies acute pulmonary embolism by hemodynamics, sPESI/PESI, right-heart function, and troponin, and gives the reperfusion or anticoagulation direction per ESC 2019.

Open guideline tool →

For licensed clinicians. Not a substitute for clinical judgement.

Share on XLinkedInWhatsAppEmail

Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.

Related guideline tools

For use by licensed clinicians and clinical researchers. Computed locally in your browser — no data is uploaded. Not a substitute for clinical judgement.